WOCKHARDT

$WOCKPHARMA share price extended its rally for the second straight session on Tuesday, December 2, rising 6.5% after the company announced a historic regulatory milestone for its novel antibiotic Zaynich. This surge comes after Monday’s sharp 19.21% jump, taking the two-day rally to nearly 27% and placing the pharma major firmly back in investor focus. The company revealed in an exchange filing that the United States Food and Drug Administration (US FDA) has formally accepted its New Drug Application (NDA) for Zaynich—a first-of-its-kind achievement for any Indian pharmaceutical company. But on wednesday we saw a profit booking session the script whichh led to a fall in price by around 5%.